- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00536588
A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)
March 26, 2015 updated by: Merck Sharp & Dohme LLC
A Phase 1 Study of the Safety and Tolerability of Intravesical Administration of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder
The purpose of this first-in-human study is to determine the safety and tolerability of SCH 721015 in subjects with transitional cell carcinoma of the bladder.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A nonrandomized, open-label, rising-dose, parallel-group, multi-center study of SCH 721015 in patients with papillary bladder cancer, or carcinoma in situ that is refractory to Bacillus Calmette-Guerin.
Subjects will receive a single intravesical administration of SCH 721015 with SCH 209702 in a total volume of 75 mL with a 1-hour dwell time.
Subjects who at 3 months post administration demonstrate a complete response (CR on cystoscopy/biopsy and cytology) and who did not experience dose-limiting toxicity will be allowed to receive a second intravesical administration at the same dose level.
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically proven recurrent transitional cell carcinoma of the bladder, Stage Tis, Ta.
- Patients with recurrent T1 disease who do not wish to have cystectomy.
- Subjects must have failed at least two prior courses of BCG with or without recombinant interferon alpha administration.
- At least 3 months must have passed since last intravesical treatment for bladder carcinoma.
- Subjects must be 18 years of age or older.
- Life expectancy of at least 3 months.
- Adequate performance status (Karnofsky score >=70%).
- Adequate laboratory values.
Exclusion Criteria:
- Suspected hypersensitivity to interferon alpha.
- Subjects with organ transplants.
Any known preexisting medical condition that could interfere with the subject's participation in and completion of the study such as:
- History of psychosis or presence of poorly controlled depression;
- CNS trauma or active seizure disorders requiring medication;
- Significant cardiovascular dysfunction within the past 6 months including symptomatic cardiac ischemia, arrhythmia or congestive heart failure requiring hospitalization or emergency room visit within last 3 months;
- Poorly controlled diabetes mellitus (HbA1C >10.0%);
- Unstable chronic pulmonary disease requiring hospitalization or emergency room visit within the last 3 months;
- Immunologically mediated disease (eg, rheumatoid arthritis, autoimmune hepatitis, immune mediated glomerulonephritis).
- History of any clinically significant local or systemic infectious disease within 4 weeks prior to initial treatment administration.
- Untreated bladder infection.
- Positive for hepatitis BsAg or HIV Ab or hepatitis C.
- Immunosuppressive therapy within the last 3 months.
- BCG therapy or intravesical therapy within 3 months.
- Traumatic catheterization within 1 month.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SCH 721015 with SCH 209702
|
Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10^9 to 3 x 10^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events, laboratory safety tests, dose-limiting toxicity
Time Frame: CBC/chemistry: predose, Days 1-3, 7, 14, 21, & 28, Week 12.
|
CBC/chemistry: predose, Days 1-3, 7, 14, 21, & 28, Week 12.
|
Adverse events, laboratory safety tests, dose-limiting toxicity
Time Frame: Additional hematology on Days 4, 5, & 6.
|
Additional hematology on Days 4, 5, & 6.
|
Adverse events, laboratory safety tests, dose-limiting toxicity
Time Frame: AEs: Duration of study; up to 3 years postdose for serious events.
|
AEs: Duration of study; up to 3 years postdose for serious events.
|
Adverse events, laboratory safety tests, dose-limiting toxicity
Time Frame: ECG and VS - predose and selected postdose time points.
|
ECG and VS - predose and selected postdose time points.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Timed urine collections for IFNα2b excretion & IP-10.
Time Frame: Days 1-7, 10, 14, 21, & 28/29.
|
Days 1-7, 10, 14, 21, & 28/29.
|
Urine samples for SCH 721015 DNA content.
Time Frame: Predose, Days 1-7 & 14.
|
Predose, Days 1-7 & 14.
|
Blood samples for SCH 721015 DNA; SCH 209702, & IFNα2b levels; antiadenoviral & anti-IFNα2b antibodies
Time Frame: Pre- & postdose for SCH 721015 DNA; SCH 721015, & IFNα2b levels; & postdose for antibodies.
|
Pre- & postdose for SCH 721015 DNA; SCH 721015, & IFNα2b levels; & postdose for antibodies.
|
Urine cytology & FISH
Time Frame: Days 1, 30 & 90
|
Days 1, 30 & 90
|
Cystoscopy & bladder biopsies
Time Frame: Screening & Day 90
|
Screening & Day 90
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (ACTUAL)
August 1, 2009
Study Completion (ACTUAL)
August 1, 2009
Study Registration Dates
First Submitted
September 26, 2007
First Submitted That Met QC Criteria
September 26, 2007
First Posted (ESTIMATE)
September 28, 2007
Study Record Updates
Last Update Posted (ESTIMATE)
March 27, 2015
Last Update Submitted That Met QC Criteria
March 26, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P03816
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Neoplasms
-
Peking University First HospitalRecruitingUrinary Bladder Cancer | Bladder Cancer | Bladder Neoplasms | Bladder Tumors | Neoplasms, BladderChina
-
Mansoura UniversityCompletedBladder Cancer | Bladder Disease | Bladder Neoplasm | Micro-RNAEgypt
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Medical Enterprises Ltd.TerminatedUrinary Bladder Cancer | Bladder Cancer | Malignant Tumor of Urinary Bladder | Bladder Neoplasm | Cancer of Bladder | Carcinoma in Situ of Bladder | Bladder Tumors | Cancer of the Bladder | Neoplasms, Bladder | Papillary Carcinoma of Bladder (Diagnosis) | BCG-Unresponsive Bladder CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Baylor College of MedicinePfizerTerminatedBladder Cancer | Invasive Bladder Cancer | Metastatic Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
Clinical Trials on SCH 721015 with SCH 209702
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); FKD Therapies Oy of FinlandCompleted
-
Merck Sharp & Dohme LLCCompletedPrimary Hypercholesterolemia | Mixed Hyperlipidemia
-
ALK-Abelló A/SCompleted
-
National Cancer Institute (NCI)Active, not recruitingStage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Lentigo Maligna Melanoma | Mucosal Melanoma | Acral Lentiginous Melanoma | Cutaneous Nodular Melanoma | Low-CSD MelanomaUnited States
-
Merck Sharp & Dohme LLCCompletedLymphoma, Non-Hodgkin | Multiple Myeloma | Solid Tumors | Leukemia, Lymphocytic, Chronic. B-Cell
-
Merck Sharp & Dohme LLCWithdrawn
-
ALK-Abelló A/SCompletedConjunctivitis | Rhinitis Allergic
-
M.D. Anderson Cancer CenterSchering-PloughWithdrawnGlioblastoma
-
Merck Sharp & Dohme LLCCompleted